ProCE Banner Activity

CALIBRATE: Wk 54 Primary Analysis of Long-Acting Subcutaneous Lenacapavir in Treatment-Naive Patients

Slideset Download
Conference Coverage
Two regimens featuring a subcutaneous lenacapavir backbone administered every 6 months conferred complete virologic suppression in 85% to 90% of patients at Week 54.

Released: February 18, 2022

Expiration: February 17, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck & Co., Inc.

ViiV Healthcare